| Literature DB >> 36235094 |
Fengming Lin1, Chenyang Jia1, Fu-Gen Wu1.
Abstract
Despite the remarkable significance and encouraging breakthroughs of intracellular enzyme-instructed self-assembly of peptides (IEISAP) in disease diagnosis and treatment, a comprehensive review that focuses on this topic is still desirable. In this article, we carefully review the advances in the applications of IEISAP, including the development of various bioimaging techniques, such as fluorescence imaging, photoacoustic imaging, magnetic resonance imaging, positron-emission tomography imaging, radiation imaging, and multimodal imaging, which are successfully leveraged in visualizing cancer tissues and cells, bacteria, and enzyme activity. We also summarize the utilization of IEISAP in disease treatments, including anticancer, antibacterial, and antiinflammation applications, among others. We present the design, action modes, structures, properties, functions, and performance of IEISAP materials, such as nanofibers, nanoparticles, nanoaggregates, and hydrogels. Finally, we conclude with an outlook towards future developments of IEISAP materials for biomedical applications. It is believed that this review may foster the future development of IEISAP with better performance in the biomedical field.Entities:
Keywords: antibacterial; bioimaging; cancer theranostics; hydrogel; nanostructure; peptide
Mesh:
Substances:
Year: 2022 PMID: 36235094 PMCID: PMC9571778 DOI: 10.3390/molecules27196557
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Scheme 1IEISAP for various imaging and disease treatment applications.
Figure 1IEISAP for fluorescence imaging. (a) Molecular structures of the soluble precursor and the fiber-forming building block. The soluble precursor can be desuccinylated by SIRT5 to generate the fiber-forming building block. (b) Scheme illustrating the intracellular fiber formation in mitochondria via the specific interaction of the internalized peptide precursors with the SIRT5 enzyme, as well as the effect of the formation of nanofibers on the depolarization of mitochondrial membrane potential and promotion of ROS generation. Reprinted/adapted with permission from [44]. Copyright 2020, American Chemical Society.
Figure 2IEISAP for PA imaging. (a) Chemical structure and proposed chemical conversion of 1-RGD to 1-cycl, as well as the self-assembly of 1-cycl to nanoparticles. (b) Scheme depicting the mechanism of using 1-RGD for PA imaging of caspase-3 activity in apoptotic tumor cells. (c) Jablonski diagram of the proposed mechanism to amplify PA signal by augmenting nonradiative relaxation of the excited ICG fluorophores within nanoparticles. Reprinted/adapted with permission from [66]. Copyright 2019, John Wiley & Sons, Inc.
Figure 3IEISAP for MRI. (a) Structural diagram of compound 1. The red arrow indicates the furin-mediated cleavage site, while the blue arrow points to the GSH reduction site. (b) Schematic demonstration of intracellular furin/GSH-regulated generation of IONP aggregates from IONP@1 for improved transverse relaxation rate (R2) and release of TFMB-Arg-Val-Arg-Arg-OH residues for turning on the 19F NMR/MRI signal. Reprinted/adapted with permission from [72]. Copyright 2019, John Wiley & Sons, Inc.
Figure 4Schematic description of an ALP-activatable NIR fluorescence (FL)/MR bimodal probe for in vivo imaging. (a) Chemical structure of P-CyFF-Gd, the ALP-regulated fluorogenic reaction of P-CyFF-Gd, and in situ self-assembly of CyFF-Gd into NPs that displayed enhanced NIR FL and r1 relaxivity. (b) Proposed mechanism of P-CyFF-Gd for NIR FL/MR bimodal imaging of ALP-expressing tumor cells in vivo. Reprinted/adapted with permission from [80]. Copyright 2019, American Chemical Society.
IEISAP materials used as anticancer drugs directly.
| Peptide | Enzyme | Structures | Cell Death | Cancer Cells | Mechanism | Properties | Ref. |
|---|---|---|---|---|---|---|---|
| dNapFFYp | ALP | Hydrogel/nanonet | Apoptosis | HeLa, MES-SA, and MES-SA/Dx5 | Blocking cellular mass exchange | High selectivity and accumulation in cancer cells | [ |
| NBD-FFYpK-TPP | ALP | Nanofiber | Apoptosis | Saos2 | Causing mitochondrial dysfunction to release cytochrome c | Mitochondria-targeting; no drug resistance | [ |
| QKVPHVGQK/QKAPGVGQK | TGase | Hydrogel | Apoptosis | HeLa, MCF-7, and SH-SY5Y | Preventing the diffusion and assembly of actin in the cytoplasm and damaging the existing actin filaments | Increased accumulation and retention effects | [ |
| D-Tetrapeptides | ALP | Nanofiber | Apoptosis | Saos2 | Significant rearrangement of cytoskeletal proteins and plasma membranes | – | [ |
| dNapFFYp | ALP | Nanofiber | Apoptosis | HeLa, MES-SA/Dx5, T98G, and A2780-cis | Presenting autocrine proapoptotic ligands to their cognate receptors in a juxtacrine manner, as well as directly clustering the death receptors | Killing multidrug-resistant cancer cells | [ |
| Nap-ffypeMe2 | ALP | Nanoparticle and/or nanofibril * | Apoptosis | Saos-2 | Countering immunosuppression in the tumor microenvironment | Immunotherapy; inhibiting metastatic osteosarcoma | [ |
| NapGDFDFpYSV | ALP | Nanofiber | Apoptosis | HeLa and A549 | Inhibiting histone deacetylase andimproving the accumulation of acetylated histone | Enhanced cellular uptake and high selectivity | [ |
| GFFYG | ALP and reductase | Nanofiber | Apoptosis | A549 | Mitochondrial membrane disruption that results in increased ROS, cytochrome C release, and endoplasmic reticulum stress | Inhibiting lung cancer cells | [ |
| F-pY-T | ALP | Nanoparticle | Apoptosis | CT26 | Inducing mitochondrial oxidative stress that leads to immunogenic cell death | Mitochondria-targeting and cancer immunotherapy | [ |
| NYSKPTDRQYHF | ALP | Nanofiber | Apoptosis | 4T1 | Selective degradation of PD-L1 in cancer cells | Selective degradation of PD-L1 | [ |
| L- and D-dipeptide and taurine conjugates | CES | Nanofiber | Apoptosis or necroptosis | HCC1937, SKOV3, and A2780-cis | Disrupting the dynamics of actin filaments | High selectivity to cancer cells; killing resistant cancer cells | [ |
| Phosphorylated D-tetrapeptide (NapDFDFDYDY) | ALP | Nanofiber | Apoptosis and necroptosis | Saos2 | Interactions between nanofibers and the death receptors | – | [ |
| D-Phosphotyrosine conjugated with cholesterol | ALP | Nanoparticle | Apoptosis and necroptosis | HeLa, A2780, and A2780-cis | Interacting with actin filaments and microtubules and affecting lipid rafts | Killing drug-resistant ovarian cancer cells | [ |
| Nap-GFFpYSV | ALP | Nanofiber | Apoptosis | HeLa and A549 | Damaging DNA and arresting cell cycles | Selectively enhancing radiosensitivity of cancer; combinatorial chemo-photodynamic therapy | [ |
| Nap-FFFYp | ALP | Nanofiber | Necroptosis | Saos-2 | Dramatically disrupting cytoskeletons and acitvating NF-κB | NF-κB targeting; low dosage | [ |
| GKGSFGFTG | ATG4B | – | Autophagy | MCF-7 | Autophagy-mediated chemotherapy using doxorubicin | Chemotherapy | [ |
| Nap-FF-NHCH2CH2OH | MMP-7 | – | – | HeLa | Cellular stress | – | [ |
| Nap-FF-NHCH2CH2OH | Esterase | – | – | HeLa | Cellular stress | – | [ |
| Nap-ffy | CES and ALP | Nanofiber | – | Hep G2 and OVSAHO | Targeting downregulation in cancer cells | Treating metastatic cancers | [ |
| Olsalazine-RVRR | Furin | nanoparticle | – | HCT116 | Inhibiting DNA methylation | Minimal effusion | [ |
| KYDKKKKDG(Nap-ffky) | Trypsin | Nanofiber | Apoptosis and necroptosis | OVSAHO | Inducing endoplasmic reticulum stress | Targeting endoplasmic reticulum | [ |
| Nap-GFFpYSV (precursor 1) and Nap-GFFpYIGSR (precursor 2) | ALP | Nanofiber and hydrogel | – | A549 and HeLa | – | – | [ |
Abbreviations: ALP: alkaline phosphatase; ATG4B: autophagy-related 4 homolog B; CES: carboxylesterase; MMP-7: matrix metalloproteinase-7; NF-κB: nuclear factor-kappa B; PD-L1: programmed death ligand-1; TGase: transglutaminase. * Concentration-dependent.
Figure 5An IEISAP precursor Cyp-HCQ-Yp for autophagy inhibition-facilitated mild-temperature PTT. (a) Molecular structure of Cyp-HCQ-Yp and its enzymatic conversions. (b) Scheme depicting the working mechanism of Cyp-HCQ-Yp for autophagy inhibition-facilitated mild-temperature PTT. (c) Molecular structures of two control compounds HCQ-Yp and Cyp-Yp. Reprinted/adapted with permission from [115]. Copyright 2021, John Wiley & Sons, Inc.
Figure 6IEISAP for anticancer combination therapy. (a) Chemical structure of the precursor D-1 and its enzymatic transformation into nanofibers. The D-1 molecules themselves were innocuous to cells at optimal concentrations, but they could double or triple the activity of cisplatin toward drug-resistant ovarian cancer cells. Reprinted/adapted with permission from [117]. Copyright 2015, John Wiley & Sons, Inc. (b) Scheme showing the enzymatic self-assembly of pTP-Me, which induces cellular stress to activate NF-κB signaling for cell survival, as well as the combination of IEISAP and NF-κB targeting for effectively killing cancer cells. Reprinted/adapted with permission from [97]. Copyright 2018, American Chemical Society.
Figure 7Scheme depicting the structure of the Pt(IV) prodrug with a built-in apoptosis probe and its working mechanism of the early determination of its therapeutic effect in situ. Reprinted/adapted with permission from [53]. Copyright 2014, American Chemical Society.
Figure 8(a) Scheme illustrating the self-assembly of CPCs and the mechanism of enzyme-triggered morphological transformation. (b) Accumulation and in situ morphological transformation of CPC-based nanoparticles in the bacteria-infected site of the mouse. Reprinted/adapted with permission from [119]. Copyright 2017, John Wiley & Sons, Inc.
Figure 9Schematic presentation showing the NQO1-responsive self-amplifying assembly of peptides in macrophages. Reprinted/adapted with permission from [121]. Copyright 2022, American Chemical Society.